Loading
Latest filing published 02 Oct 2026 for 메타바이오메드.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
윤종필 is a declared insider of 메타바이오메드 (chief executive), with filings sourced from DART (FSS). We count 7 filings; the first trade dates from 3 February 2026 and the latest from 2 October 2026.
On the market, this insider has only ever bought: 7 purchases, €1,687 in total. The totals do not cover 5 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
The record was last updated on 2 October 2026 with an open-market purchase in 메타바이오메드. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations